Literature DB >> 29331235

Antimüllerian hormone as a predictor of live birth following assisted reproduction: an analysis of 85,062 fresh and thawed cycles from the Society for Assisted Reproductive Technology Clinic Outcome Reporting System database for 2012-2013.

Reshef Tal1, David B Seifer1, Ethan Wantman2, Valerie Baker3, Oded Tal4.   

Abstract

OBJECTIVE: To determine if serum antimüllerian hormone (AMH) is associated with and/or predictive of live birth assisted reproductive technology (ART) outcomes.
DESIGN: Retrospective analysis of Society for Assisted Reproductive Technology Clinic Outcome Reporting System database from 2012 to 2013.
SETTING: Not applicable. PATIENT(S): A total of 69,336 (81.8%) fresh and 15,458 (18.2%) frozen embryo transfer (FET) cycles with AMH values. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Live birth. RESULT(S): A total of 85,062 out of 259,499 (32.7%) fresh and frozen-thawed autologous non-preimplantation genetic diagnosis cycles had AMH reported for cycles over this 2-year period. Of those, 70,565 cycles which had embryo transfers were included in the analysis. Serum AMH was significantly associated with live birth outcome per transfer in both fresh and FET cycles. Multiple logistic regression demonstrated that AMH is an independent predictor of live birth in fresh transfer cycles and FET cycles when controlling for age, body mass index, race, day of transfer, and number of embryos transferred. Receiver operating characteristic (ROC) curves demonstrated that the areas under the curve (AUC) for AMH as predictors of live birth in fresh cycles and thawed cycles were 0.631 and 0.540, respectively, suggesting that AMH alone is a weak independent predictor of live birth after ART. Similar ROC curves were obtained also when elective single-embryo transfer (eSET) cycles were analyzed separately in either fresh (AUC 0.655) or FET (AUC 0.533) cycles, although AMH was not found to be an independent predictor in eSET cycles. CONCLUSION(S): AMH is a poor independent predictor of live birth outcome in either fresh or frozen embryo transfer for both eSET and non-SET transfers.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ART; Antimüllerian hormone (AMH); elective single embryo transfer (eSET); frozen embryo transfer; live birth

Mesh:

Substances:

Year:  2018        PMID: 29331235     DOI: 10.1016/j.fertnstert.2017.10.021

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  14 in total

Review 1.  Ovarian Reserve Testing: A Review of the Options, Their Applications, and Their Limitations.

Authors:  Nicole D Ulrich; Erica E Marsh
Journal:  Clin Obstet Gynecol       Date:  2019-06       Impact factor: 2.190

Review 2.  Anti-müllerian hormone as a predictor for live birth among women undergoing IVF/ICSI in different age groups: an update of systematic review and meta-analysis.

Authors:  Ni-Jie Li; Qing-Yun Yao; Xiao-Qiong Yuan; Yong Huang; Yu-Feng Li
Journal:  Arch Gynecol Obstet       Date:  2022-07-30       Impact factor: 2.493

3.  Follicular fluid anti-Müllerian hormone (AMH) concentrations and outcomes of in vitro fertilization cycles with fresh embryo transfer among women at a fertility center.

Authors:  Caitlin R Sacha; Jorge E Chavarro; Paige L Williams; Jennifer Ford; LiHua Zhang; Patricia K Donahoe; Irene C Souter; Russ Hauser; David Pépin; Lidia Mínguez-Alarcón
Journal:  J Assist Reprod Genet       Date:  2020-10-06       Impact factor: 3.412

4.  Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF.

Authors:  Jialyu Huang; Jiaying Lin; Hongyuan Gao; Yun Wang; Xiuxian Zhu; Xuefeng Lu; Bian Wang; Xinyan Fan; Renfei Cai; Yanping Kuang
Journal:  Front Endocrinol (Lausanne)       Date:  2019-05-28       Impact factor: 5.555

5.  Anti-Müllerian Hormone Gene Polymorphism is Associated with Clinical Pregnancy of Fresh IVF Cycles.

Authors:  Cheng-Hsuan Wu; Shun-Fa Yang; Hui-Mei Tsao; Yu-Jun Chang; Tsung-Hsien Lee; Maw-Sheng Lee
Journal:  Int J Environ Res Public Health       Date:  2019-03-08       Impact factor: 3.390

6.  Counseling young women with early breast cancer on fertility preservation.

Authors:  M E Elena Ter Welle-Butalid; I J H Ingeborg Vriens; J G Josien Derhaag; E M Edward Leter; C E Christine de Die-Smulders; M Marjolein Smidt; R J T Ron van Golde; V C G Vivianne Tjan-Heijnen
Journal:  J Assist Reprod Genet       Date:  2019-11-23       Impact factor: 3.412

7.  An Ovarian Reserve Assessment Model Based on Anti-Müllerian Hormone Levels, Follicle-Stimulating Hormone Levels, and Age: Retrospective Cohort Study.

Authors:  Huiyu Xu; Li Shi; Guoshuang Feng; Zhen Xiao; Lixue Chen; Rong Li; Jie Qiao
Journal:  J Med Internet Res       Date:  2020-09-21       Impact factor: 5.428

8.  Age-specific definition of low anti-Mullerian hormone and associated pregnancy outcome in women undergoing IVF treatment.

Authors:  Depeng Zhao; Jing Fan; Ping Wang; Xuan Jiang; Jilong Yao; Xuemei Li
Journal:  BMC Pregnancy Childbirth       Date:  2021-03-05       Impact factor: 3.007

9.  Unexplained infertility categorization based on female laparoscopy and total motile sperm count, and its impact on cumulative live-births after one in-vitro fertilization cycle. A retrospective cohort study involving 721 cycles.

Authors:  Ruma Satwik; Mohinder Kochhar
Journal:  Reprod Med Biol       Date:  2021-02-01

10.  Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany.

Authors:  Klaus F Bühler; Robert Fischer; Patrice Verpillat; Arthur Allignol; Sandra Guedes; Emmanuelle Boutmy; Wilma Bilger; Emilia Richter; Thomas D'Hooghe
Journal:  Reprod Biol Endocrinol       Date:  2021-06-16       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.